Scholars Central

Review articlePublished 9 Mar 2020

Coronaviruses and the Associated Potential Therapeutics for the Viral Infections

Authors: Shilei Wang, Yichi Zhang, Shuo Liu, Hongmei Peng, Vienna Mackey, Lichun Sun

1Shenzhen Academy of Peptide Targeting Technology at Pingshan and Shenzhen Tyercan Bio-Pharm Co., Ltd, Guangdong, China; 2Department of Medicine, School of Medicine, Tulane University Health Sciences Center, New Orleans, USA; 3Sino-US Innovative Bio-Medical Center and Hunan Beautide Pharmaceuticals, Hunan, China; 4Scientific Research and Education Department, The First Peoples Hospital of Changde City, Changde, China

Journal of Infectious Diseases & Therapy

Volume 8 · Issue 2 · Pages 1–8

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Coronaviruses (CoVs), named after the crown-like spikes on their surfaces, belong to the RNA virus family Coronaviridae. Coronaviruses are enveloped RNA viruses with a linear positive-sense single–stranded genome consisting of the open reading frames (ORFs), the 5’- methylated cap, and the 3’- poly (A) tail. The open reading frames encode structural proteins and nonstructural proteins that may be drug-targetable. Antiviral medications seek to target these key proteins via different mechanisms. There have been seven coronaviruses discovered that are capable of infecting human beings, three of which including MERS-CoV, SARS-CoV and SARS-CoV-2, originated in wild animals and evolved to develop rapid human-to-human transmission, resulting in severe respiratory diseases among other pathologies, even deaths. Particularly, the outbreak of the novel Wuhan coronavirus SARS-CoV-2 has now rapidly spread across China and into many other countries. Sadly, there is no any effective vaccine or specific drug available. Many patients infected with SARS-CoV-2 have succumbed. Thus, there is a burning need for the anti-coronavirus drug development. The antiviral prodrug, Remdesivir, developed by the company Gilead, is currently under clinical investigation in China.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Infectious Diseases & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Infectious Diseases & Therapy
  • SubjectInfectious Diseases
  • BylineArticles whose byline prints “Shilei Wang”
  • BylineArticles whose byline prints “Yichi Zhang”
  • BylineArticles whose byline prints “Shuo Liu”
  • BylineArticles whose byline prints “Hongmei Peng”
  • BylineArticles whose byline prints “Vienna Mackey”
  • BylineArticles whose byline prints “Lichun Sun”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels